Pacira BioSciences Statistics
Total Valuation
PCRX has a market cap or net worth of $876.37 million. The enterprise value is $1.07 billion.
Important Dates
The last earnings date was Wednesday, November 6, 2024, after market close.
| Earnings Date | Nov 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
PCRX has 46.17 million shares outstanding. The number of shares has increased by 0.49% in one year.
| Current Share Class | 46.17M |
| Shares Outstanding | 46.17M |
| Shares Change (YoY) | +0.49% |
| Shares Change (QoQ) | -8.72% |
| Owned by Insiders (%) | 1.03% |
| Owned by Institutions (%) | 112.46% |
| Float | 45.67M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 7.15 |
| PS Ratio | 1.26 |
| Forward PS | 1.33 |
| PB Ratio | 1.17 |
| P/TBV Ratio | 2.83 |
| P/FCF Ratio | 4.53 |
| P/OCF Ratio | 4.30 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 5.99, with an EV/FCF ratio of 5.51.
| EV / Earnings | n/a |
| EV / Sales | 1.54 |
| EV / EBITDA | 5.99 |
| EV / EBIT | 10.46 |
| EV / FCF | 5.51 |
Financial Position
The company has a current ratio of 2.25, with a Debt / Equity ratio of 0.86.
| Current Ratio | 2.25 |
| Quick Ratio | 1.81 |
| Debt / Equity | 0.86 |
| Debt / EBITDA | 3.33 |
| Debt / FCF | 3.33 |
| Interest Coverage | 6.68 |
Financial Efficiency
Return on equity (ROE) is -11.48% and return on invested capital (ROIC) is 4.53%.
| Return on Equity (ROE) | -11.48% |
| Return on Assets (ROA) | 4.17% |
| Return on Capital (ROIC) | 4.53% |
| Revenue Per Employee | $976,063 |
| Profits Per Employee | -$127,431 |
| Employee Count | 712 |
| Asset Turnover | 0.45 |
| Inventory Turnover | 2.45 |
Taxes
In the past 12 months, PCRX has paid $35.82 million in taxes.
| Income Tax | 35.82M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -39.69% in the last 52 weeks. The beta is 0.80, so PCRX's price volatility has been lower than the market average.
| Beta (5Y) | 0.80 |
| 52-Week Price Change | -39.69% |
| 50-Day Moving Average | 17.64 |
| 200-Day Moving Average | 21.70 |
| Relative Strength Index (RSI) | 54.08 |
| Average Volume (20 Days) | 932,988 |
Short Selling Information
The latest short interest is 4.80 million, so 10.39% of the outstanding shares have been sold short.
| Short Interest | 4.80M |
| Short Previous Month | 4.82M |
| Short % of Shares Out | 10.39% |
| Short % of Float | 10.50% |
| Short Ratio (days to cover) | 8.62 |
Income Statement
In the last 12 months, PCRX had revenue of $694.96 million and -$90.73 million in losses. Loss per share was -$1.96.
| Revenue | 694.96M |
| Gross Profit | 439.58M |
| Operating Income | 102.01M |
| Pretax Income | 100.55M |
| Net Income | -90.73M |
| EBITDA | 178.03M |
| EBIT | 102.01M |
| Loss Per Share | -$1.96 |
Full Income StatementBalance Sheet
The company has $453.81 million in cash and $644.42 million in debt, giving a net cash position of -$190.61 million or -$4.13 per share.
| Cash & Cash Equivalents | 453.81M |
| Total Debt | 644.42M |
| Net Cash | -190.61M |
| Net Cash Per Share | -$4.13 |
| Equity (Book Value) | 749.58M |
| Book Value Per Share | 16.24 |
| Working Capital | 383.57M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $203.84 million and capital expenditures -$10.32 million, giving a free cash flow of $193.53 million.
| Operating Cash Flow | 203.84M |
| Capital Expenditures | -10.32M |
| Free Cash Flow | 193.53M |
| FCF Per Share | $4.19 |
Full Cash Flow StatementMargins
Gross margin is 63.25%, with operating and profit margins of 14.68% and -13.06%.
| Gross Margin | 63.25% |
| Operating Margin | 14.68% |
| Pretax Margin | -7.90% |
| Profit Margin | -13.06% |
| EBITDA Margin | 25.62% |
| EBIT Margin | 14.68% |
| FCF Margin | 27.85% |
Dividends & Yields
PCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.49% |
| Shareholder Yield | -0.49% |
| Earnings Yield | -10.35% |
| FCF Yield | 22.08% |
Dividend DetailsAnalyst Forecast
The average price target for PCRX is $26.60, which is 40.15% higher than the current price. The consensus rating is "Buy".
| Price Target | $26.60 |
| Price Target Difference | 40.15% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | -4.82% |
| EPS Growth Forecast (5Y) | 15.84% |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PCRX has an Altman Z-Score of 1.73 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.73 |
| Piotroski F-Score | 6 |